The Efficacy and Tolerability of Acarbose in Healthy Individuals

The Efficacy and Tolerability of Acarbose in Healthy Individuals: A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05542849

Enrollment

Registered

2022-09-16

Start date

2022-08-10

Completion date

2022-10-05

Last updated

2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose Response, Side Effect, Tolerance

Brief summary

A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

Interventions

DRUGAcarbose Tablets 50mg

Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion helps keep blood glucose from rising very high after meals.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age 18-85 2. Any sex 3. Any ethnicity 4. Interest in taking Acarbose off-label 5. Approved by the AgelessRx Medical team to take Acarbose 6. Willing and technically able to use and operate a CGM 7. Own a CGM-compatible phone 8. Relatively good health with only well-managed chronic diseases (hypertension, coronary artery disease, type II diabetes, etc.) clinically stable 9. Adequate cognitive function to be able to give informed consent

Exclusion criteria

1. Diabetes of any type 2. Taking metformin or any other glucose lowering medication 3. Any uncontrolled endocrine disorder (thyroid, pancreatic, adrenal, etc...) 4. Active malignancy of any kind 5. Clinically relevant renal or kidney disease or dysfunction 6. History of eating disorder 7. Taking any medication, or has any medical condition that might interfere with the action of acarbose of the CGM sensor

Design outcomes

Primary

Measure	Time frame	Description
Monophasic glucose response	120 minutes per phase, recorded on 4 separate occasions over 2 weeks.	Blood glucose (mg/dl) response following high carbohydrate intake

Secondary

Measure	Time frame	Description
Tolerability of Side Effect	Recorded on 4 separate occasions over 2 weeks.	Tolerance of side effect profile (Scale 0 - 10) denoting no side effect at all to intolerable

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026